Devyser announced in Aug 2022 that we received our first IVDR certificate from the notified body...
With new more sensitive diagnostics, rejection of a transplanted kidney can be detected earlier,...
Devyser, the pioneering leader in diagnostic solutions, launches today its first IVDR-certified...
Hematopoietic stem cell transplantation (HSCT) is the only curative treatment for patients with...
“Further strong organic growth was reported for the year and quarter. Efforts to build an...
We are pleased to welcome Vertitas Corporation as a new distributor of the Devyser portfolio for...
Relapse of the underlying malignant disease is a major complication after hematopoietic stem cell...
This episode is dedicated to the 10-year anniversary of Genomics England's 100,000 Genomes Project...
Time is precious. Every minute, every second that we can simplify your lab’s workflow shortens the...
Conventional genetic testing for thalassemia requires the use of several techniques, leading to...
"Devyser reports yet another quarter of record sales and strong gross margins. The positive sales...
